Evolving Strategies in Hepatitis C: Cure, Prevention, and Beyond | AASLD

Evolving Strategies in Hepatitis C: Cure, Prevention, and Beyond

Nov 10 2025
Convention Center: Ballroom B, Level 3
11:00 AM - 12:30 PM

World Class Speakers

AB
Abstract Presenter

Andrea D Branch, PhD

Icahn School of Medicine at Mount Sinai (ISMMS)
Harrys A Torres, MD, FAASLD
Abstract Presenter

Harrys A Torres, MD, FAASLD

The University of Texas MD Anderson Cancer Center
AB
Moderator

Andrea D Branch, PhD

Icahn School of Medicine at Mount Sinai (ISMMS)
Harrys A Torres, MD, FAASLD
Moderator

Harrys A Torres, MD, FAASLD

The University of Texas MD Anderson Cancer Center

Description

This session highlights cutting-edge research in Hepatitis C treatment, including next-generation antivirals, optimized therapy durations, and strategies for long-term patient outcomes post-cure. Presenters will share findings from clinical trials, modeling studies, and translational research aimed at advancing the future of HCV care.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Oct 09 2026
Convention Center - Ballroom B, Level 3

Ultra-Short Glecaprevir/Pibrentasvir Plus Ezetimibe Prevents Chronic HCV in HCV-Infected Recipients of HCV-Uninfected Non-Liver Transplants: 6-Year Outcomes of the Toronto Protocol

Andrea D Branch, PhD , Abstract Presenter
Hepatitis
11:15 AM - 11:30 AM
Oct 09 2026
Convention Center - Ballroom B, Level 3

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

Harrys A Torres, MD, FAASLD , Abstract Presenter
Hepatitis
11:30 AM - 11:45 AM
Oct 09 2026
Convention Center - Ballroom B, Level 3

Multiscale modeling of results from a Phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection

Andrea D Branch, PhD , Abstract Presenter
Hepatitis
11:45 AM - 12:00 PM
Oct 09 2026
Convention Center - Ballroom B, Level 3

A multi-omic blood-based model accurately predicts liver related events in patients with cirrhosis after hepatitis C virus cure with direct acting antivirals. 

Harrys A Torres, MD, FAASLD , Abstract Presenter
Hepatitis
12:00 PM - 12:15 PM
Oct 09 2026
Convention Center - Ballroom B, Level 3

Reverse-engineering strategy identified DDR1 as HCC chemoprevention target post HCV cure

Andrea D Branch, PhD , Abstract Presenter
Hepatitis
12:15 PM - 12:30 PM
Oct 09 2026
Convention Center - Ballroom B, Level 3

Eight versus twelve weeks of sofosbuvir/velpatasvir for treatment-naïve, non-cirrhotic chronic hepatitis C: An interim analysis of a multicentric, open label, randomized, non-inferiority (RESOLVE) trial 

Harrys A Torres, MD, FAASLD , Abstract Presenter
Hepatitis

Objectives

  • Describe emerging antiviral agents and combination regimens for Hepatitis C.
  • Discuss updates on long-term outcomes related to novel HCV therapies.
  • Identify predictive tools and post-cure interventions aimed at reducing long-term liver-related complications and advancing HCV-related cancer prevention.